Enliven Therapeutics priced an upsized public offering that will bring in about $400.0 million in gross proceeds before expenses, selling 8,933,334 shares of common stock at $37.50 each.
The company also sold, in lieu of shares, pre-funded warrants for up to 1,733,333 shares at $37.499 per warrant, reflecting the $0.001 per-share exercise price. Between the common stock and the pre-funded warrants, Enliven is offering a total of 10,666,667 shares’ worth of securities.
The deal size was increased from the company’s prior plan, with Enliven also giving underwriters a 30-day option to buy up to another 1,600,000 shares at the public offering price, less underwriting discounts and commissions.
Jefferies, Goldman Sachs, Morgan Stanley and Barclays are serving as joint book-running managers. Mizuho is also a book-running manager, LifeSci Capital is a passive book-running manager, and Baird and Jones are serving as lead manager and manager, respectively.
The offering is expected to close on or about June 15, 2026. The market has reacted to these announcements by moving the company's shares 14.3% to a price of $46.13. For the full picture, make sure to review Enliven Therapeutics's 8-K report.
